The gut microbiome, probiotics, bile acids axis, and human health

Trends in Microbiology

Volumn 22, Issue 6, 2014, Pages 306-308

  Jones, Mitchell Lawrence ^a   Tomaro Duchesneau, Catherine ^a   Prakash, Satya ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BILE SALT; CHENODEOXYCHOLIC ACID; CHOLESTEROL 7ALPHA MONOOXYGENASE; DEOXYCHOLIC ACID; FARNESOID X RECEPTOR; LITHOCHOLIC ACID; PROBIOTIC AGENT; BILE ACID; LIGAND;

BIFIDOBACTERIUM BREVE; BIFIDOBACTERIUM LONGUM; BIFIDOBACTERIUM LONGUM INFANTIS; BILE ACID METABOLISM; COLONY FORMING UNIT; ENVIRONMENTAL FACTOR; GASTROINTESTINAL TRACT; HUMAN; LACTOBACILLUS ACIDOPHILUS; LACTOBACILLUS DELBRUECKII; LACTOBACILLUS PARACASEI; LACTOBACILLUS PLANTARUM; MICROBIAL METABOLISM; MICROBIOME; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SHORT SURVEY; STREPTOCOCCUS THERMOPHILUS; BIOLOGICAL MODEL; DRUG EFFECTS; METABOLISM; MICROFLORA; SECRETION (PROCESS);

BILE ACIDS AND SALTS; HUMANS; LIGANDS; MICROBIOTA; MODELS, BIOLOGICAL; PROBIOTICS;

EID: 84901589576     PISSN: 0966842X     EISSN: 18784380     Source Type: Journal    
DOI: 10.1016/j.tim.2014.04.010     Document Type: Short Survey

References (10)

1. Duboc H., et al. Connecting dysbiosis, bile-acid dysmetabolism and gut inflammation in inflammatory bowel diseases. Gut 2013, 62:531-539.
2. Theriot C.M., et al. Antibiotic-induced shifts in the mouse gut microbiome and metabolome increase susceptibility to Clostridium difficile infection. Nat. Commun. 2014, 5:3114.
3. Sayin S.I., et al. Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist. Cell Metab. 2013, 17:225-235.
4. De Aguiar Vallim T.Q., et al. Pleiotropic roles of bile acids in metabolism. Cell Metab. 2013, 17:657-669.
5. Degirolamo C., et al. Microbiota modification with probiotics induces hepatic bile acid synthesis via downregulation of the Fxr-Fgf15 axis in mice. Cell Rep. 2014, 7:12-18.
6. Jones M.L., et al. Cholesterol lowering and inhibition of sterol absorption by Lactobacillus reuteri NCIMB 30242: a randomized controlled trial. Eur. J. Clin. Nutr. 2012, 66:1234-1241.
7. Lepercq P., et al. Bifidobacterium animalis strain DN-173 010 hydrolyses bile salts in the gastrointestinal tract of pigs. Scand. J. Gastroenterol. 2004, 39:1266-1271.
8. Jones M.L., et al. Cholesterol-lowering efficacy of a microencapsulated bile salt hydrolase-active Lactobacillus reuteri NCIMB 30242 yoghurt formulation in hypercholesterolaemic adults. Br. J. Nutr. 2012, 107:1505-1513.
9. Marteau P., et al. Bifidobacterium animalis strain DN-173 010 shortens the colonic transit time in healthy women: a double-blind, randomized, controlled study. Aliment. Pharmacol. Ther. 2002, 16:587-593.
10. Jones M.L., et al. Cholesterol lowering with bile salt hydrolase-active probiotic bacteria, mechanism of action, clinical evidence, and future direction for heart health applications. Expert Opin. Biol. Ther. 2013, 13:631-642.